SI-BONE's iFuse TORQ TNT Implant System Receives FDA Clearance for Pelvic Fragility Fractures
Key Insights
SI-BONE's iFuse TORQ TNT implant system (search) has received FDA 510(k) clearance, offering a novel solution for pelvic fragility fractures (search).
The TNT system is designed to address the specific anatomical and bone mineral density needs of the sacrum and ilium, potentially improving treatment outcomes.
TNT's design aims to enhance early fixation and reduce screw backout, facilitating earlier patient weight-bearing and mobilization post-surgery.
SI-BONE, Inc. has secured FDA 510(k) clearance for its iFuse TORQ TNT implant system (search), a pioneering anatomy-specific system developed to tackle the biomechanical challenges associated with pelvic fragility fractures (search). The FDA's decision indicates that TNT holds the potential to offer more effective treatment compared to the current standard of care, which often involves cannulated screws. This clearance underscores SI-BONE's commitment to creating unique solutions for substantial unmet clinical needs.
Design and Functionality of the TNT Implant System
The TNT implant system is meticulously engineered to cater to the specific anatomical and bone mineral density requirements of the sacrum and ilium. The system features a porous threaded implant with lengths capable of traversing the posterior pelvis, extending through the ipsilateral ilium and sacrum, and reaching into the contralateral ilium. A specialized system is incorporated to mitigate the rate of screw backout, a common concern in these procedures.
One of the key advantages of TNT is its ability to improve early fixation and minimize screw backout, potentially enabling patients to bear weight and mobilize sooner after surgery. This positions TNT as a next-generation technology for both pelvic fragility fracture fixation and sacroiliac joint fusion.
Notably, the FDA previously granted TNT a Breakthrough Device Designation, highlighting its potential impact on patient care.
Market Growth and Opportunities
According to a report by Grand View Research, the global sacroiliac joint fusion market was valued at $721.2 million in 2023 and is projected to grow at a CAGR of 19.8% from 2024 to 2030. This growth is primarily driven by the increasing prevalence of lower back pain, buttocks pain, groin pain, and lower extremity pain, as well as technological advancements and a rising incidence of sacroiliitis (search) or sacroiliac joint dysfunction (search).
Further contributing to market expansion are advancements in minimally invasive surgical techniques, improvements in insurance coverage, and proactive initiatives by major companies in the field. SI-BONE's progress with the TNT system is strategically timed to capitalize on this market potential.
Recent Developments
In May 2024, SI-BONE broadened its iFuse Bedrock Granite implant system (search) portfolio with the introduction of Granite 9.5, which followed FDA 510(k) premarket clearance in January. Granite 9.5 is designed for patients with smaller anatomies, facilitating easier placement of stacked implants in the sacroalar-iliac trajectory.